About Hypertension Drugs
Hypertension, or high blood pressure (BP), develops when there is too much pressure against the inner walls of blood vessels. Depending on the pressure exerted, hypertension can be classified as:
• PAH
• Systemic hypertension (commonly referred to as hypertension)
PAH, high BP in the arteries that carry blood from the heart to the lungs, occurs when blood vessels narrow, making blood flow difficult. This creates pressure on the heart's right ventricle, which increases in size and becomes weaker due to the excess load, leading to heart failure. The normal pulmonary arterial pressure at rest is 14 mmHg and increases from 25 mmHg to 30 mmHg.
Systemic hypertension occurs when blood vessels that supply oxygenated blood to the body become narrower, creating pressure on the right side of the heart. Hypertension can lead to damaged organs and illnesses such as renal failure (kidney failure), aneurysm, heart failure, stroke, or heart attack. Hypertension is classified into two types:
• Primary or essential hypertension: It is defined as high BP with no known cause, and includes around 90%-95% of all hypertension cases
• Secondary hypertension: It is high BP with a known direct cause, including kidney disease, tumors, or birth control pills, and includes 5%-10% of all hypertension cases
Technavio’s analysts forecast the global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global hypertension drugs market for 201652020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent hypertension and pulmonary arterial hypertension (PAH).
The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC
Technavio's report, Global Hypertension Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Actelion Ltd.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Company, Ltd.
• Novartis AG
• Sanofi SA
Other prominent vendors
• Actelion Pharmaceuticals
• Arena Pharmaceuticals
• Asahi Kasei
• Bayer HealthCare
• Bellerophon Therapeutics
• Bial
• CJ HealthCare
• Conatus Pharmaceuticals
• Daiichi Sankyo
• Deka Pharmaceuticals
• Dong-A ST
• Eiger BioPharmaceuticals
• Forest Laboratories
• Gilead Sciences
• HanAll BioPharma
• Hanmi Pharmaceutical
• Johnson & Johnson
• LG Life Sciences
• Lung Biotechnology
• Lupin Pharmaceuticals
• Mast Therapeutics
• Merck
• Northern Therapeutics
• Ono Pharmaceutical
• Pfizer
• PhaseBio
• Pluristem Therapeutics
• Quantum Genomics
• Radikal Therapeutics
• Reata Pharmaceuticals
• Serodus
• sigma-tau i.f.r
• SteadyMed Therapeutics
• Suda
• Sun Pharmaceutical Industries
• Symplmed Pharmaceuticals
• Takeda Pharmaceuticals
• United Therapeutics
• Valeant Pharmaceuticals
• XOMA
• Yuhan
Market driver
• Growing older population
• For a full, detailed list, view our report
Market challenge
• Patent expiries of major drugs
• For a full, detailed list, view our report
Market trend
• Increase in awareness
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Key buying criteria
PART 05: Cardiovascular drugs market
• Global pharmaceuticals market
• Global cardiovascular drugs market
PART 06: Overview: Hypertension
• Systemic hypertension
• PAH
PART 07: Epidemiology and economic burden
• Economic burden
PART 08: Pipeline portfolio
PART 09: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 10: Market segmentation by type
• Global systemic hypertension drugs market
• Global PAH drugs market
PART 11: Market segmentation by drug class
• Systemic hypertension
• PAH
PART 12: Geographical segmentation
• Global hypertension drugs market by geographical segmentation 2015-2020
• Hypertension drugs market in Americas
• Hypertension drugs market in EMEA
• Hypertension drugs market in APAC
PART 13: Market drivers
• Growing older population
• Rise in sedentary lifestyle
• High prevalence of chronic conditions
• Patient assistance programs
PART 14: Impact of drivers
PART 15: Market challenges
• Patent expiries of major drugs
• Adverse effects
• Poor patient compliance
• Availability of alternative therapies
PART 16: Impact of drivers and challenges
PART 17: Market trends
• Increase in awareness
• Increased focus on combination therapies
• Intense competition among vendors
• Strategic alliances
PART 18: Vendor landscape
• Competitive scenario
• Market share 2015
• Novartis
• Daiichi Sankyo
• Actelion Pharmaceuticals
• Boehringer Ingelheim
• Sanofi
• AstraZeneca
• Other prominent vendors
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for drugs that treat hypertension
Exhibit 03: Patent expiries of major cardiovascular drugs
Exhibit 04: Global cardiovascular drugs market by generic and branded drugs sales 2015
Exhibit 05: Top 10 companies in global cardiovascular drugs market 2014
Exhibit 06: Pathophysiology of hypertension
Exhibit 07: Treatment algorithm for hypertension
Exhibit 08: Prevalence of PAH by cause
Exhibit 09: Projected prevalence of CVDs in US 2010-2030 (% of population)
Exhibit 10: Prevalence of hypertension in US population 2010-2030 (% of population)
Exhibit 11: Projected direct and indirect burden of hypertension in US 2010-2030 ($ billions)
Exhibit 12: Projected mortality trend for CVDs globally 2015 and 2030
Exhibit 13: Pipeline portfolio: Global systemic hypertension drugs
Exhibit 14: Pipeline portfolio: Global PAH drugs
Exhibit 15: Market share of global hypertension drugs in global pharmaceutical market 2015
Exhibit 16: Global hypertension drugs market 2015-2020 ($ billions)
Exhibit 17: Five forces analysis
Exhibit 18: Global hypertension drugs market segmentation by type 2015
Exhibit 19: Global systemic hypertension drugs market 2015-2020 ($ billions)
Exhibit 20: Global PAH drugs market 2015-2020 ($ billions)
Exhibit 21: Segmentation of global hypertension drugs market by drug class
Exhibit 22: Global systemic hypertension drugs market share by drug class 2015
Exhibit 23: Global PAH drugs market share by drug class 2015
Exhibit 24: Segmentation of global hypertension drugs market based on geography 2015
Exhibit 25: Hypertension drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 26: Percentage share of hypertension drugs market by geography 2015-2020
Exhibit 27: Hypertension drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Hypertension drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Hypertension drugs market in APAC 2015-2020 ($ billions)
Exhibit 30: Global hypertension drugs market: YoY growth rate and revenue based on geography 2015-2020
Exhibit 31: Population aged 60 years and over: World, developed, and developing regions ($ millions)
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Sales of major drugs in global hypertension drugs market 2014 ($ billions)
Exhibit 35: Novartis: YoY growth rate and revenue of Diovan 2012-2015 ($ billions)
Exhibit 36: Novartis: YoY growth rate and revenue of Exforge 2012-2015 ($ billions)
Exhibit 37: Novartis: Key takeaways
Exhibit 38: Daiichi Sankyo: YoY growth rate and revenue of Olmetec in Japan 2012-2014 ($ millions)
Exhibit 39: Daiichi Sankyo: YoY growth rate and revenue of Olmetec/Olmetec Plus in Europe 2012-2014 ($ millions)
Exhibit 40: Daiichi Sankyo: YoY growth rate and revenue of Rezaltas in Japan 2012-2014 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY growth rate and revenue of Artist in Japan 2012-2014 ($ millions)
Exhibit 42: Daiichi Sankyo: YoY growth rate and revenue of Benicar/Benicar HCT in US 2012-2014 ($ millions)
Exhibit 43: Daiichi Sankyo: YoY growth rate and revenue of AZOR in US 2012-2014 ($ millions)
Exhibit 44: Daiichi Sankyo: YoY growth rate and revenue of TRIBENZOR in US 2012-2014 ($ millions)
Exhibit 45: Daiichi Sankyo: YoY growth rate and revenue of Sevikar in Europe 2012-2014 ($ millions)
Exhibit 46: Daiichi Sankyo: YoY growth rate and revenue of Sevikar HCT in Europe 2012-2014 ($ millions)
Exhibit 47: Daiichi Sankyo: Key takeaways
Exhibit 48: Actelion Pharmaceuticals: YoY growth rate and revenue of Tracleer 2011-2014 ($ billions)
Exhibit 49: Actelion Pharmaceuticals: YoY revenue of Opsumit 2013 and 2014 ($ millions)
Exhibit 50: Actelion Pharmaceuticals: YoY growth rate and revenue of Ventavis 2011-2014 ($ millions)
Exhibit 51: Actelion Pharmaceuticals: YoY growth rate and revenue of Veletri 2011-2014 ($ millions)
Exhibit 52: Actelion Pharmaceuticals: Key takeaways
Exhibit 53: Boehringer Ingelheim: YoY growth rate and revenue of Micardis 2012-2014 ($ millions)
Exhibit 54: Boehringer Ingelheim: Key takeaways
Exhibit 55: Sanofi: YoY growth rate and revenue of Aprovel 2012-2014 ($ millions)
Exhibit 56: Sanofi: YoY growth rate and revenue of Tritace 2012-2014 ($ millions)
Exhibit 57: Sanofi: YoY growth rate and revenue of Lasix 2012-2014 ($ millions)
Exhibit 58: Sanofi: Key takeaways
Exhibit 59: AstraZeneca: Business segmentation by revenue 2015
Exhibit 60: AstraZeneca: YoY growth rate and revenue of Seloken/Toprol 2013-2015 ($ millions)
Exhibit 61: AstraZeneca: YoY growth rate and revenue of Atacand 2013-2015 ($ millions)
Exhibit 62: AstraZeneca: YoY growth rate and revenue of Tenormin 2012-2014 ($ millions)
Exhibit 63: AstraZeneca: Key takeaways
